Rutgers Cancer Institute of New Jersey ( Site 1059) — New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 1059) is a clinical research site located in New Brunswick, New Jersey, United States 08903.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Rutgers Cancer Institute of New Jersey ( Site 1059) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: High-risk Non-muscle Invasive Bladder Cancer.

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rutgers Cancer Institute of New Jersey ( Site 1059)?

Rutgers Cancer Institute of New Jersey ( Site 1059) has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rutgers Cancer Institute of New Jersey ( Site 1059) conducted?

Rutgers Cancer Institute of New Jersey ( Site 1059) has 1 clinical trials on record, with 1 currently active. Their work covers High-risk Non-muscle Invasive Bladder Cancer.

Is Rutgers Cancer Institute of New Jersey ( Site 1059) accredited by Crixeo Health?

Rutgers Cancer Institute of New Jersey ( Site 1059) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rutgers Cancer Institute of New Jersey ( Site 1059)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.